Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hirudins: from leeches to man

R B Wallis1

  • 1Biopharm (UK) Ltd, Bryngelen Manor, Hendy, Dyfed, United Kingdom.

Seminars in Thrombosis and Hemostasis
|January 1, 1996
PubMed
Summary

Recombinant hirudins, derived from medicinal leeches, are potent anticoagulants that show promise in treating thrombosis. These compounds exhibit significant effectiveness against various thrombi types, with ongoing clinical trials suggesting advantages over existing antithrombotic therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduction of plasma clot stability by a novel factor XIIIa inhibitor from the Giant Amazon Leech, Haementeria ghilianii.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·1997
Same author

Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii.

The Biochemical journal·1997
Same author

Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro.

Thrombosis and haemostasis·1997
Same author

Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·1993
Same author

The effect of recombinant hirudin on arterial thrombosis.

Advances in experimental medicine and biology·1993
Same author

A non-occlusive model of arterial thrombus formation in the rat and its modification by inhibitors of platelet function, or thrombin activity.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·1992

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Hirudins are homologous polypeptides from the medicinal leech (Hirudo medicinalis) with high affinity for thrombin.
  • They act as potent anticoagulants by inhibiting thrombin-induced platelet aggregation and thrombin bound to fibrin clots.

Purpose of the Study:

  • To evaluate the effects of recombinant hirudins on thrombosis in animal models.
  • To assess the potential clinical applications of recombinant hirudins in various thrombotic conditions.

Main Methods:

  • Production of recombinant hirudins.
  • Testing in animal models of thrombosis.
  • Analysis of effects on venous-type and arterial thrombi.
  • Clinical trials in deep venous thrombosis, acute coronary syndrome, and myocardial infarction.

Main Results:

  • Recombinant hirudins demonstrate broad efficacy in animal thrombosis models.
  • They are particularly effective against venous thrombi and superior to heparins for arterial thrombi.
  • Pilot clinical trials show promising advantages over current antithrombotic agents.

Conclusions:

  • Recombinant hirudins represent a promising new class of antithrombotic agents.
  • Ongoing clinical trials are investigating their efficacy in major thrombotic diseases.
  • Further research and larger trials are anticipated to confirm their therapeutic potential.

Related Experiment Videos